Medical therapies for pulmonary arterial hypertension
| Autor: | Karen Plascencia, Nayeli Zayas, Maitane Alonso de Mendieta, Jennifer Escobar, Tomás Pulido |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Endothelin Receptor Antagonists
Hypertension Pulmonary Prostacyclin Vasodilation 030204 cardiovascular system & hematology Pharmacology Nitric Oxide Riociguat 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Humans Endothelial dysfunction Serotonin Antagonists Macitentan Randomized Controlled Trials as Topic Sulfonamides Endothelin-1 business.industry Drugs Investigational Phosphodiesterase 5 Inhibitors medicine.disease Endothelin 1 Pulmonary hypertension Epoprostenol Pyrimidines 030228 respiratory system chemistry Drug Therapy Combination Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Heart failure reviews. 21(3) |
| ISSN: | 1573-7322 |
| Popis: | Pulmonary Arterial hypertension (PAH) is a chronic and progressive disease characterized by an increase in pulmonary vascular resistance due to severe remodeling of the small pulmonary arteries. In PAH, the endothelial cells fail to maintain their homeostatic balance, with the consequent impaired production of vasodilators and over-expression of vasoconstrictors and proliferators. Current treatment of PAH is based on the discovery of three main pathways of endothelial dysfunction (prostacyclin, nitric oxide and endothelin-1), and includes drugs such as prostacyclin analogs, phosphodiesterase-5 inhibitors and endothelin receptor antagonists (ERAs). Recently approved drugs that act through these classic pathways include riociguat (cyclic GMP stimulator) and macitentan (a tissue specific dual ERA). However, several new drugs and new pathways are under study. New targeted therapies include tyrosine kinase inhibitors, Rho kinase inhibitors and serotonin receptor blockers. There are now ten drugs approved for the treatment of PAH that, alone or in combination, have changed the natural history of this disease. The new drugs will allow us to further modified the patients' life expectancy and move towards a cure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink